March 29 (Reuters) - Shire Plc:
* ANNOUNCED EUROPEAN MEDICINES AGENCY HAS VALIDATED ITS MARKETING AUTHORIZATION APPLICATION FOR LANADELUMAB (SHP643)
* REPORTS THAT HEALTH CANADA HAS COMPLETED SCREENING AND ACCEPTED NEW DRUG SUBMISSION UNDER PRIORITY REVIEW FOR INVESTIGATIONAL COMPOUND
* HEALTH CANADA’S RECENT ACCEPTANCE OF LANADELUMAB NDS FOR PRIORITY REVIEW SHORTENS REVIEW TIMELINE FROM 300 TO 180 DAYS Source text for Eikon: Further company coverage: